000276280 001__ 276280
000276280 005__ 20250204165928.0
000276280 0247_ $$2doi$$a10.1007/s12035-024-04365-4
000276280 0247_ $$2pmid$$apmid:39012444
000276280 0247_ $$2ISSN$$a0893-7648
000276280 0247_ $$2ISSN$$a1559-1182
000276280 037__ $$aDZNE-2025-00259
000276280 041__ $$aEnglish
000276280 082__ $$a570
000276280 1001_ $$00000-0002-2380-527X$$aOwona, Brice Ayissi$$b0$$eFirst author
000276280 245__ $$aBiflavonoid Methylchamaejasmin and Khaya grandifoliola Extract Inhibit NLRP3 Inflammasome in THP-1 Cell Model of Neuroinflammation.
000276280 260__ $$aTotowa, NJ$$bHumana Press$$c2025
000276280 3367_ $$2DRIVER$$aarticle
000276280 3367_ $$2DataCite$$aOutput Types/Journal article
000276280 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738671434_26729
000276280 3367_ $$2BibTeX$$aARTICLE
000276280 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276280 3367_ $$00$$2EndNote$$aJournal Article
000276280 520__ $$aNeuroinflammation is a common hallmark of Alzheimer's disease (AD), with NLRP3 inflammasome proven to be activated in microglia of AD patients' brains. In this study, a newly isolated biflavonoid (7,7'-di-O-methylchamaejasmin/M8) and a crude extract of the plant Khaya grandifoliola (KG) were investigated for their inhibitory effect on inflammasome activation. In preliminary experiments, M8 and KG showed no cytotoxicity on human macrophage-like differentiated THP-1 cells and exhibited anti-inflammatory inhibition of nitric oxide produced following lipopolysaccharide stimulation. Furthermore, M8 and KG blocked IL-1β and IL-18 production by reducing NLRP3 inflammasome components including NFκB, NLRP3, Caspase-1, pro-IL-1β, and pro-IL-18 at the mRNA and protein levels. Regarding the formation of ASC (apoptosis-associated speck-like protein containing a CARD) specks during inflammasome activation, the size and fluorescent intensity of the existing specks were unchanged across all treatment conditions. However, M8 and KG treatments were shown to prevent further speck formation. In addition, experiments on amyloid β phagocytosis showed that M8 and KG pretreatments can restore the phagocytic activity of THP-1 cells, which was impaired following inflammasome activation. Altogether, our findings describe for the first time a promising role of biflavonoids and KG extract in preventing inflammasome activation and protecting against neuroinflammation, a key factor in AD development.
000276280 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000276280 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276280 650_7 $$2Other$$aKhaya grandifoliola
000276280 650_7 $$2Other$$a7,7′-di-O-Methylchamaejasmin
000276280 650_7 $$2Other$$aBiflavonoid
000276280 650_7 $$2Other$$aNLRP3 inflammasome
000276280 650_7 $$2Other$$aTHP-1 cells
000276280 650_7 $$2NLM Chemicals$$aNLR Family, Pyrin Domain-Containing 3 Protein
000276280 650_7 $$2NLM Chemicals$$aInflammasomes
000276280 650_7 $$2NLM Chemicals$$aPlant Extracts
000276280 650_7 $$2NLM Chemicals$$aBiflavonoids
000276280 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000276280 650_7 $$2NLM Chemicals$$aLipopolysaccharides
000276280 650_7 $$031C4KY9ESH$$2NLM Chemicals$$aNitric Oxide
000276280 650_7 $$2NLM Chemicals$$aInterleukin-1beta
000276280 650_2 $$2MeSH$$aHumans
000276280 650_2 $$2MeSH$$aNLR Family, Pyrin Domain-Containing 3 Protein: metabolism
000276280 650_2 $$2MeSH$$aInflammasomes: metabolism
000276280 650_2 $$2MeSH$$aInflammasomes: drug effects
000276280 650_2 $$2MeSH$$aPlant Extracts: pharmacology
000276280 650_2 $$2MeSH$$aTHP-1 Cells
000276280 650_2 $$2MeSH$$aBiflavonoids: pharmacology
000276280 650_2 $$2MeSH$$aBiflavonoids: therapeutic use
000276280 650_2 $$2MeSH$$aNeuroinflammatory Diseases: drug therapy
000276280 650_2 $$2MeSH$$aNeuroinflammatory Diseases: metabolism
000276280 650_2 $$2MeSH$$aNeuroinflammatory Diseases: pathology
000276280 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000276280 650_2 $$2MeSH$$aLipopolysaccharides: pharmacology
000276280 650_2 $$2MeSH$$aMeliaceae: chemistry
000276280 650_2 $$2MeSH$$aPhagocytosis: drug effects
000276280 650_2 $$2MeSH$$aNitric Oxide: metabolism
000276280 650_2 $$2MeSH$$aInterleukin-1beta: metabolism
000276280 7001_ $$00000-0002-6597-766X$$aMary, Arnaud$$b1
000276280 7001_ $$00000-0002-9184-2080$$aMessi, Angelique N$$b2
000276280 7001_ $$0P:(DE-2719)9002244$$aRavichandran, Kishore Aravind$$b3
000276280 7001_ $$00000-0002-1427-979X$$aMbing, Josephine Ngo$$b4
000276280 7001_ $$00000-0001-5431-621X$$aPegnyemb, Emmanuel$$b5
000276280 7001_ $$00000-0002-2694-5569$$aMoundipa, Paul F$$b6
000276280 7001_ $$0P:(DE-2719)2000008$$aHeneka, Michael$$b7$$eLast author
000276280 773__ $$0PERI:(DE-600)2079384-4$$a10.1007/s12035-024-04365-4$$gVol. 62, no. 2, p. 1605 - 1619$$n2$$p1605 - 1619$$tMolecular neurobiology$$v62$$x0893-7648$$y2025
000276280 8564_ $$uhttps://pub.dzne.de/record/276280/files/DZNE-2025-00259_Restricted.pdf
000276280 8564_ $$uhttps://pub.dzne.de/record/276280/files/DZNE-2025-00259_Restricted.pdf?subformat=pdfa$$xpdfa
000276280 909CO $$ooai:pub.dzne.de:276280$$pVDB
000276280 9101_ $$0I:(DE-588)1065079516$$60000-0002-2380-527X$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000276280 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002244$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000276280 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000008$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000276280 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000276280 9141_ $$y2025
000276280 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000276280 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000276280 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000276280 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000276280 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000276280 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000276280 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000276280 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000276280 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000276280 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000276280 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL NEUROBIOL : 2022$$d2025-01-07
000276280 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL NEUROBIOL : 2022$$d2025-01-07
000276280 9201_ $$0I:(DE-2719)1011303$$kAG Heneka$$lNeuroinflammation, Biomarker$$x0
000276280 980__ $$ajournal
000276280 980__ $$aVDB
000276280 980__ $$aI:(DE-2719)1011303
000276280 980__ $$aUNRESTRICTED